Explore the HER2CLIMB-05 study's findings on tucatinib's impact on breast cancer progression-free survival, enhancing treatment options for pharmacists.
Erika Hamilton, MD
Advertisement
Articles by Erika Hamilton, MD
Compared with fulvestrant, vepdegestrant significantly extended progression-free survival and improved response rates.
Advertisement
Latest Updated Articles
HER2CLIMB-05: Tucatinib Added to Maintenance HP Extends PFS in HER2+ Metastatic Breast CancerPublished: December 11th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5